# Natera awarded national MRD testing contract by U.S. Department of Veterans Affairs

Natera was awarded a nationwide contract by the U.S. Department of Veterans Affairs National Precision Oncology Program to provide minimal residual disease testing services using its Signatera test. The contract is effective September 15, 2022.

- Type: Contract
- Announced: 2022-11-02
- Where: United States
- Status: completed
- Products: minimal residual disease testing, Signatera test
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [U.S. Department of Veterans Affairs](https://endata.com/companies/22244.md) (customer)
- [Natera](https://endata.com/companies/66374.md) (supplier)

## Sources

- [prnewswire.com](https://www.prnewswire.com/news-releases/natera-awarded-national-mrd-testing-contract-by-the-us-department-of-veterans-affairs-301665809.html), 2022-11-02: "We are proud to partner with the VA to make Signatera accessible to our nation's veterans."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.